Nan Fung Life Sciences and Novo have taken part in the immuno-oncology drug developer's series B round, which was led by Pivotal BioVenture Partners.

US-based cancer therapeutics developer Bolt Biotherapeutics closed a $54m series B round yesterday featuring pharmaceutical firm Novo and Nan Fung Life Sciences, a subsidiary of property development group Nan Fung. The round was led by Pivotal BioVenture Partners, the life science investment vehicle set up by Nan Fung, and included investment firm Vivo Capital. Founded…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.